A continuació, deixem l'assaig clínic que va portar a l'aprovació del fàrmac per la FDA. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core a… https://t.co/ECz0Kqgpkz
RT @JIMD_Editors: From Dec 2018: Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from t…
RT @JIMD_Editors: From Dec 2018: Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from t…
From Dec 2018: Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double‐blind, randomised, placebo‐controlled trial Borgwardt et al h
Efficacy and safety of Velmanase alfa in the treatment of patients with alpha… https://t.co/bLBIaSpTqo #eprompt #OT
RT @JIMD_Editors: Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from the core and ext…
RT @JIMD_Editors: Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from the core and ext…
Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double‐blind, randomised, placebo‐controlled trial [OPEN ACCESS] https://t.co/WtazEox
Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial https://t.co/FCH19ImEnL